C WorldWide Group Holding A S Has $11.95 Million Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• C WorldWide Group increased its Boston Scientific stake by 55.6% in the second quarter, purchasing 100,000 additional shares for a total position valued at approximately $11.95 million. Institutional investors own 89.07% of the company.
• Analyst sentiment remains broadly positive, with 24 Buy, five Hold and two Sell ratings producing a consensus “Moderate Buy” rating and an average price target of $71.62. Boston Scientific also reported quarterly earnings and revenue above estimates and authorized a $5 billion share-repurchase plan.
• A cyberattack disrupted global manufacturing and shipments, prompting the company to warn that it will miss its 2026 guidance and creating uncertainty around upcoming sales and profits. The stock opened at $45, near its 52-week low of $42.20, while company insiders bought roughly $9.4 million of shares over the past 90 days.

C WorldWide Group Holding A S increased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 55.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 280,000 shares of the medical equipment provider's stock after purchasing an additional 100,000 shares during the quarter. C WorldWide Group Holding A S's holdings in Boston Scientific were worth $11,950,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter worth approximately $26,000. Main Street Financial Solutions LLC boosted its holdings in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock worth $812,000 after buying an additional 1,971 shares in the last quarter. Ieq Capital LLC grew its position in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock worth $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC boosted its stake in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock worth $763,000 after acquiring an additional 2,556 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BSX. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday, July 30th. UBS Group reduced their price target on shares of Boston Scientific from $74.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Needham & Company LLC decreased their price target on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a research note on Wednesday, July 8th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Weiss Ratings cut shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a report on Tuesday, July 7th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $71.62.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward Ludwig purchased 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael Mahoney acquired 186,240 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing, shipping and other global operations are recovering, which could limit the disruption’s duration. The company also continues to point to multiple product launches and cost savings as potential longer-term growth drivers. Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided replacement targets for its third-quarter or full-year 2026 outlook. Investors will likely focus on the pace of operational recovery and the size of the eventual revenue and profit shortfall. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: The cyberattack disrupted manufacturing and order shipments worldwide, creating a material expected impact on third-quarter and full-year 2026 results. The warning raises the risk of lower sales, reduced operating leverage and an earnings miss relative to prior guidance. Boston Scientific Won't Meet Guidance Due to Cyberattack
• Negative Sentiment: Beyond the immediate cyberattack effects, analysts noted pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses, weakening the company’s 2026 growth outlook. That near-term uncertainty outweighs the longer-term benefit expected from new product launches and cost initiatives. Boston Scientific's 2026 Growth Outlook Weakens

Boston Scientific Stock Down 5.9%

BSX stock opened at $45.00 on Wednesday. The stock has a fifty day moving average of $47.04 and a 200-day moving average of $55.18. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company has a market capitalization of $65.22 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the firm earned $0.75 earnings per share. The company's revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.